- Delivering Pan India
Jakavi® (Ruxolitinib) Ruxolitinib 5 mg and Ruxolitinib 10 mg and Ruxolitinib 15 mg and Ruxolitinib 20 mg tablets by Novartis. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Ruxolitinib 5 mg / Ruxolitinib 10 mg / Ruxolitinib 15 mg / Ruxolitinib 20 mg |
|---|---|
| Manufacturer | Novartis |
| Country | Switzerland |
| Pack size | Ruxolitinib 5 mg: 56 tablets (as shown on the carton); Ruxolitinib 10 mg: Please confirm current pack; Ruxolitinib 15 mg: Please confirm current pack; Ruxolitinib 20 mg: Please confirm current pack |
| Storage | Store in original pack as per carton instructions |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Jakavi® (Ruxolitinib) Ruxolitinib 5 mg and Ruxolitinib 10 mg and Ruxolitinib 15 mg and Ruxolitinib 20 mg Tablets — JAK1/JAK2 Kinase Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Jakavi® is a brand of ruxolitinib tablets, a Janus kinase (JAK) inhibitor, marketed by Novartis. According to the US prescribing information for the same active ingredient (Jakafi®, Incyte), ruxolitinib is indicated for intermediate or high-risk myelofibrosis, polycythaemia vera in adults with an inadequate response to or intolerance of hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in defined patients. Indications for Jakavi in India and elsewhere are defined by its approved pack insert and each regulator. The decision to prescribe ruxolitinib, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Jakavi® (ruxolitinib) Ruxolitinib 5 mg and Ruxolitinib 10 mg and Ruxolitinib 15 mg and Ruxolitinib 20 mg tablets to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Jakavi contains ruxolitinib, an oral kinase inhibitor. The carton shown is the Novartis Jakavi 5 mg pack of 56 tablets; Jakavi is also supplied in higher strengths.
How it works, according to the label: The reference label describes ruxolitinib as an inhibitor of Janus-associated kinases JAK1 and JAK2, which are involved in signalling of cytokines and growth factors important for blood cell formation and immune function.
The current US prescribing information for Jakafi® (ruxolitinib; same active ingredient) (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Jakavi pack insert.
The studies below are summarised as published; they describe the evidence for ruxolitinib and are not a recommendation for any patient.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Ruxolitinib 5 mg | Tablets (oral) | 56 tablets (as shown on the carton) |
| Ruxolitinib 10 mg | Tablets (oral) | Please confirm current pack |
| Ruxolitinib 15 mg | Tablets (oral) | Please confirm current pack |
| Ruxolitinib 20 mg | Tablets (oral) | Please confirm current pack |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, haematology and oncology department buyers, and pharmacies that source specialty oral products. Ruxolitinib is prescribed and supervised by a physician, as described in the prescribing information.
The Jakafi label reports that, in myelofibrosis and polycythaemia vera, the most common haematologic adverse reactions (more than 20%) are thrombocytopenia and anaemia, and the most common non-haematologic reactions (15% or more) are bruising, dizziness, headache and diarrhoea. Warnings listed include thrombocytopenia, anaemia and neutropenia, risk of infection, symptom exacerbation after interruption or discontinuation, non-melanoma skin cancer and lipid elevations. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Jakavi carton and leaflet. For reference, the US label for Jakafi describes storage at 20°C to 25°C in a tight container, protected from light.
Jakavi is marketed by Novartis. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Jakavi through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Jakavi available in India?
A.K. Pharma supplies Jakavi (ruxolitinib) Ruxolitinib 5 mg and Ruxolitinib 10 mg and Ruxolitinib 15 mg and Ruxolitinib 20 mg tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Jakavi contain?
Ruxolitinib, a JAK1/JAK2 inhibitor, in 5, 10, 15 and 20 mg tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Jakavi be stored?
As printed on the carton and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
